ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2842

Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control

Sangmee Bae1, Ilana Golub 2, Jennifer Wang 3, Ani Shahbazian 2, Srinivasa Reddy 3 and Christina Charles-Schoeman 4, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA Medical Center, Los Angeles, 4University of California, Los Angeles, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Idiopathic Inflammatory Myopathies (IIM), lipids and PON1

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Inflammation and damage to the vascular endothelium are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis. Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)- associated enzyme, which normally protects the vascular endothelium from damage due to oxidized phospholipids, which accumulate under conditions of oxidative stress. The current work evaluates PON1 activity in IIM patients compared to healthy controls.

Methods: In a cross sectional analysis of 169 patients with IIM and 112 healthy controls we measured plasma PON1 activity using the arylesterase assay (Clin Chim Acta. 402(1-2):67-74, 2009). Lipoprotein cholesterol levels, inflammatory markers, and myositis autoantibodies(ab) were assessed by standard assays, and myositis disease activity was assessed using physician global 100 mm visual analogue scales (VAS) and CPK levels.

Results: Patients with IIM had significantly lower PON1 activity compared to healthy controls (Table 1). Univariate analysis of PON1 activity in IIM patients showed associations of lower PON1 activity with higher disease activity measured by VAS and CPK, as well as with the presence of antisynthetase antibodies (Table 2).  PON1 activity remained strongly associated with IIM diagnosis and myositis disease activity measures after multivariate adjustment for demographic factors (age, gender, race) and factors that were significantly different in univariate analysis (Table 3).

Conclusion: In a large cross sectional cohort of IIM patients, plasma PON1 activity was significantly lower than healthy controls of similar demographics, and was associated with myositis disease activity. Low PON1 activity has been previously associated with increased vascular risk and may warrant further investigation for its role in perpetuation of vascular damage in IIM patients.


PON1Table 1

*p<0.05 on chi-square test for categorical variables and Wilcoxon rank-sum test for continuous variables. ESR, erythrocyte sedimentation rate; hsCRP, high sensitivity C-Reactive Protein, CPK, creatine phosphokinase
# Ab testing available in 112 subjects


PON1Table 2

Median -IQR- unless specified
# avail in 161; ¶ avail in 171; ‡ avail in 168; § avail in 112


PON1Table 3

Model 1 including IIM and HC -N=281-, Model 2 including IIM only -N=169- with disease activity measured as VAS, Model 3 including IIM only with disease activity measured as CPK.
For Model 2, although Total cholesterol and HDL were both significant in univariate analysis, only HDL was included in the model as the two lipid variables were significantly correlated.


Disclosure: S. Bae, None; I. Golub, None; J. Wang, None; A. Shahbazian, None; S. Reddy, None; C. Charles-Schoeman, Abbvie, 2, AbbVie, 2, Amgen, 5, BMS, 2, Bristol Myers Squibb, 2, Gilead, 5, Octapharma, 2, 5, Pfizer, 2, 5, Regeneron, 5, Regeneron/Sanofi, 5, Sanofi, 5.

To cite this abstract in AMA style:

Bae S, Golub I, Wang J, Shahbazian A, Reddy S, Charles-Schoeman C. Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/paraoxonase-1-activity-is-abnormal-in-patients-with-idiopathic-inflammatory-myopathies-and-associates-with-poor-disease-control/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/paraoxonase-1-activity-is-abnormal-in-patients-with-idiopathic-inflammatory-myopathies-and-associates-with-poor-disease-control/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology